Navigation Links
AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
Date:4/28/2010

Kenney & McCafferty Represent Whistleblower Dr. Stefan Kruszewski

(PRWEB) April 28, 2010 -- AstraZeneca has agreed to pay $520 million in civil fines, penalties and damages to settle allegations that the company defrauded Medicare, Medicaid and other government-funded health care programs in connection with its marketing and promotional practices for the blockbuster atypical antipsychotic Seroquel (U.S. ex rel. STEFAN KRUSZEWSKI, MD v. ASTRAZENECA PHARMACEUTICALS, LP., Eastern District of Pennsylvania, C.A. No. 06-4004.). This is the largest settlement of off-label marketing claims brought under the False Claims Act to date that involved civil-only fines. The $520 million settlement resolves a qui tam lawsuit filed by whistleblower Dr. Stefan Kruszewski, one of two relators to file a case. Dr. Kruszewski was represented by Brian Kenney and Tavy Deming of the Kenney & McCafferty law firm, along with William Leonard of Obermayer, Rebmann, Maxwell & Hippel.

Seroquel, a potent atypical antipsychotic, was FDA-approved only for two narrow uses in adults, schizophrenia and manic episodes associated with bipolar I disorder, at the time that Dr. Kruszewski filed his complaint. Harvard-trained psychiatrist Dr. Kruszewski alleged, however, that AstraZeneca engaged in an egregious, long term off-label marketing scheme by specifically targeting children and the elderly when those uses were never properly tested or approved by the FDA and that AstraZeneca marketed the drug for a litany of off-label uses, including depression, anxiety, ADHD and insomnia.

Dr. Kruszewski's complaint further alleged that AstraZeneca arranged for clinical trials that embellished efficacy data and also downplayed the drug’s serious side effects. Dr. Kruszewski alleged that AstraZeneca used these studies to stifle physician concerns about the drug's serious treatment-emergent side effects, including type II diabetes, hyperglycemia, cardiovascular complications, heart attacks, stroke, and, in some cases, an increase in the risk of mortality.

“The manipulation and misuse of Seroquel scientific data to support AstraZeneca’s off-label marketing campaign was the most disturbing aspect of the case to me,” Dr. Kruszewski said. “There were strong indications from AstraZeneca’s earliest clinical trials that Seroquel increased the risk of diabetes and induced profound sedation out of proportion to its weak antipsychotic effects.”

Kruszewski added that “rather than properly warning doctors and the public, AstraZeneca intentionally covered up the evidence on diabetes and other serious side effects and used the sedative property of Seroquel as a selling point.” “In the elderly population, they basically marketed Seroquel as an expensive sleeping pill and put hundreds of thousands of patients at risk for serious medical complications, premature cardiovascular disease, pneumonias, and premature death.”

“This was a well thought out marketing campaign that operated on many levels,” stated Brian Kenney. “AstraZeneca orchestrated scientific studies, ghost written articles, and the payment of large fees to academic psychiatrists to act as ‘thought leaders’ to promote the drug off label. The success can be seen in the huge numbers the campaign generated with 4.9 billion in sales in 2009.” “It’s particularly disconcerting that AstraZeneca successfully co-opted large portions of psychiatric academic community,” added Mr. Kenney.

“From the outset of this case, Dr. Kruszewski was passionate about bringing to light AstraZeneca’s concealment of unfavorable Seroquel studies as well as the company’s’ improper use of what he deemed to be flawed scientific studies to promote the drug off label,” said Tavy Deming.

The U.S. Attorney's Office for the Eastern District of Pennsylvania conducted the federal investigation into AstraZeneca's Seroquel marketing practices under the direction of U.S. Attorney Michael Levy, Assistant U.S. Attorneys Virginia Gibson and Colin Cherico.

U.S. ex rel. STEFAN KRUSZEWSKI, MD v. ASTRAZENECA PHARMACEUTICALS, LP., Eastern District of Pennsylvania, C.A. No. 06-4004.

Call Tavy Deming or Brian P. Kenney at 610-940-0327 to arrange availability for the complete news release or other public material related to the case.

About Kenney & McCafferty, P.C. (http://www.quitam-lawyer.com)

Kenney & McCafferty ("K&M") specializes in qui tam and tax whistleblower litigation. K&M represents whistleblowers nationwide and has recovered more than $4 billion for the government in False Claims Act and tax whistleblower cases. Recent K&M pharmaceutical False Claims Act settlements include Pfizer, Inc./Geodon; Eli Lilly/Zyprexa; and Cephalon, Inc./Actiq, Provigil and Gabitril..

Brian P. Kenney, Esq.
Tavy Deming, Esq.
Kenney & McCafferty, P.C.
3031C Walton Road, Suite 202
Plymouth Meeting, PA 19462
610-940-0327
www.quitam-lawyer.com

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3937374.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Angel.com Launches Caller First IVR Solutions with AstraZeneca
2. PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management
3. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
4. Kaiser Permanente Gives $5 Million to Childrens Healthcare of Atlanta
5. RadioShack Customers Donate $1.3 Million to LIVESTRONG
6. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
7. Human Rights Denied: Obama Leaves 75 Million Children Behind
8. NVHR: Administrations 2011 Budget Proposal Shortchanges Five Million Americans Afflicted with Chronic Viral Hepatitis
9. State $200 Million Behind in Payments to Agencies Providing Care to Thousands of Older Illinoisans
10. Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict
11. Esperanza Health Center Receives $6.5 Million in Stimulus Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju R. ... for leading-edge care, whether or not they have a referral. Dr. Kejriwal offers ... iPlus™ laser, she targets bacteria and damaged tissue without affecting the surrounding tissue. ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that ... Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their ... orthodontics can cause for some patients, which is why they offer the latest in ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in ... on finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... help breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations ...
(Date:6/20/2017)... ... 20, 2017 , ... In his newly appointed role as ... Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s global ... and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, and ...
(Date:6/20/2017)... ... June 20, 2017 , ... Total Security Integrated Systems, ... as the partner of choice by Amtrak to fulfill several projects in various ... and long-distance intercity service in the contiguous United States. Security Executives at the ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/30/2017)... 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... Healthcare Conference on Tuesday, June 13, 2017, in ... Hill-Rom,s president and chief executive officer, is scheduled to present ... webcast can be accessed at http://ir.hill-rom.com/events.cfm . A recorded ... live event through September 13, 2017. ...
Breaking Medicine Technology: